Vol. 44 (6): 1147-1155, November – December, 2018
doi: 10.1590/S1677-5538.IBJU.2017.0629
ORIGINAL ARTICLE
Chengtao Wang 1, Zebin Chen 2, Jun Dong 1, Bixiu Wen 1, Yong Fang 2
1 Department of Radiation Oncology, First Affiliated Hospital of Sun Yat – Sen University, Guangzhou, China; 2 Department of Urology, First Affiliated Hospital of Sun Yat – Sen University, Guangzhou, China
ABSTRACT
Objective: To investigate the relationship between the pretreatment body mass index (BMI) and the clinical outcomes in patients with localized stage I – III renal cell carcinoma (RCC) surgically treated.
Materials and Methods: From January 2000 to December 2012, 798 patients with stage I – III RCC were recruited from First Affiliated Hospital and Cancer Center of Sun Yat – Sen University. Patients were divided into two groups of BMI < 25 kg / m2 or BMI ≥ 25 kg / m2 according to the World Health Organization classifications for Asian populations. The differences in the long-term survival of these two BMI groups were analyzed.
Results: The 5 – year failure – free survival rates for BMI < 25 kg / m2 and BMI ≥ 25 kg / m2 groups were 81.3% and 93.3%, respectively (P = 0.002), and the 5 – year overall survival rates were 82.5% and 93.8%, respectively (P = 0.003). BMI was a favored prognostic factor of overall survival and failure – free survival in a Cox regression model.
Conclusions: Pretreatment body mass index was an independent prognostic factor for Chinese patients surgically treated, localized stage I – III RCC.
Keywords: Body Mass Index; Carcinoma, Renal Cell; Prognosis
